{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:09:06Z","timestamp":1791140946415,"version":"4.1.0"},"reference-count":133,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:00:00Z","timestamp":1631232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["120792"],"award-info":[{"award-number":["120792"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Worldwide, cancer is a serious health concern due to the increasing rates of incidence and mortality. Conventional cancer imaging, diagnosis and treatment practices continue to substantially contribute to the fight against cancer. However, these practices do have some risks, adverse effects and limitations, which can affect patient outcomes. Although antibodies have been developed, successfully used and proven beneficial in various oncology practices, the use of antibodies also comes with certain challenges and limitations (large in size, poor tumor penetration, high immunogenicity and a long half-life). Therefore, it is vital to develop new ways to visualize, diagnose and treat cancer. Nanobodies are novel antigen-binding fragments that possess many advantageous properties (small in size, low immunogenicity and a short half-life). Thus, the use of nanobodies in cancer practices may overcome the challenges experienced with using traditional antibodies. In this review, we discuss (1) the challenges with antibody usage and the superior qualities of nanobodies; (2) the use of antibodies and nanobodies in cancer imaging, diagnosis, drug delivery and therapy (surgery, radiotherapy, chemotherapy and immunotherapy); and (3) the potential improvements in oncology practices due to the use of nanobodies as compared to antibodies.<\/jats:p>","DOI":"10.3390\/ijms22189778","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T10:31:34Z","timestamp":1631269894000},"page":"9778","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics"],"prefix":"10.3390","volume":"22","author":[{"given":"Dhaneshree Bestinee","family":"Naidoo","sequence":"first","affiliation":[{"name":"Discipline of Medical Biochemistry and Chemical Pathology, Faculty of Health Sciences, Howard College, University of Kwa-Zulu Natal, Durban 4013, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4649-4133","authenticated-orcid":false,"given":"Anil Amichund","family":"Chuturgoon","sequence":"additional","affiliation":[{"name":"Discipline of Medical Biochemistry and Chemical Pathology, Faculty of Health Sciences, Howard College, University of Kwa-Zulu Natal, Durban 4013, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,10]]},"reference":[{"key":"ref_1","unstructured":"WHO (2020). WHO Report on Cancer: Setting Priorities, Investing Wisely and Providing Care for All, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1172\/JCI31537","article-title":"A cytokine-mediated link between innate immunity, inflammation, and cancer","volume":"117","author":"Lin","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2991\/jegh.k.191008.001","article-title":"Current Cancer Epidemiology","volume":"9","author":"Mattiuzzi","year":"2019","journal-title":"J. Epidemiol. Glob. Health"},{"key":"ref_5","unstructured":"WHO (2016). Global Health Estimates 2016: Disease Burden by Cause, Age, Sex, by Country and by Region, 2000\u20132016, World Health Organization. Available online: https:\/\/www.who.int\/healthinfo\/global_burden_disease\/estimates\/en\/index1.html."},{"key":"ref_6","unstructured":"WHO (2020, October 01). International Agency for Research on Cancer. Global Cancer Observatory\u2014Cancer Fact Sheets. Available online: http:\/\/gco.iarc.fr\/today\/fact-sheets-cancers."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The Therapeutic Potential of Nanobodies","volume":"34","author":"Muyldermans","year":"2020","journal-title":"BioDrugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jconrel.2013.08.298","article-title":"Targeting tumors with nanobodies for cancer imaging and therapy","volume":"172","author":"Oliveira","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.2147\/IJN.S39428","article-title":"Nanobodies as novel agents for disease diagnosis and therapy","volume":"8","author":"Siontorou","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1517\/17425247.2014.941803","article-title":"Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer","volume":"11","author":"Xavier","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ebiom.2016.04.028","article-title":"Nanobodies as versatile tools to understand, diagnose, visualize and treat cancer","volume":"8","author":"Gettemans","year":"2016","journal-title":"EBioMedicine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1158\/1535-7163.MCT-11-0891","article-title":"Nanobodies Targeting the Hepatocyte Growth Factor: Potential New Drugs for Molecular Cancer Therapy","volume":"11","author":"Vosjan","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-07-2384","article-title":"Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: Taking advantage of modular Nanobody technology","volume":"7","author":"Tijink","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1158\/0008-5472.CAN-11-2994","article-title":"Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages","volume":"72","author":"Movahedi","year":"2012","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.3390\/cancers3033279","article-title":"Assessment of the Evolution of Cancer Treatment Therapies","volume":"3","author":"Arruebo","year":"2011","journal-title":"Cancers"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.curobgyn.2006.01.006","article-title":"Principles of chemotherapy and radiotherapy","volume":"16","author":"Symonds","year":"2006","journal-title":"Curr. Obstet. Gynaecol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/0008-5472.CAN-14-3477","article-title":"Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies","volume":"75","author":"Heskamp","year":"2015","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"10215","DOI":"10.18632\/oncotarget.7143","article-title":"A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors","volume":"7","author":"Chatterjee","year":"2016","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kobayashi, K., Sasaki, T., Takenaka, F., Yakushiji, H., Fujii, Y., Kishi, Y., Kita, S., Shen, L., Kumon, H., and Matsuura, E. (2015). A novel PET imaging using \u2076\u2074Cu-labeled monoclonal antibody against mesothelin commonly expressed on cancer cells. J. Immunol. Res. 2015.","DOI":"10.1155\/2015\/268172"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/ijc.26145","article-title":"A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth","volume":"129","author":"Roovers","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"726","DOI":"10.4161\/cbt.7.5.6097","article-title":"Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425","volume":"7","author":"Kamat","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"30384","DOI":"10.18632\/oncotarget.4672","article-title":"89Zr-cetuximab PET imaging in patients with advanced colorectal cancer","volume":"6","author":"Gootjes","year":"2015","journal-title":"Oncotarget"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2967\/jnumed.115.167155","article-title":"Immuno-PET Imaging and Radioimmunotherapy of 64Cu-\/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model","volume":"57","author":"Song","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"788","DOI":"10.2967\/jnumed.107.048538","article-title":"Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT\/micro-CT","volume":"49","author":"Gainkam","year":"2008","journal-title":"J. Nucl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1096\/fj.10-180331","article-title":"Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer","volume":"25","author":"Vaneycken","year":"2011","journal-title":"FASEB J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/cmmi.1558","article-title":"Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer","volume":"9","author":"Evazalipour","year":"2014","journal-title":"Contrast Media Mol. Imaging"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2009.26.2071","article-title":"Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer","volume":"28","author":"Krop","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"776","DOI":"10.2967\/jnumed.112.111021","article-title":"Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer","volume":"54","author":"Xavier","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7601","DOI":"10.1021\/acs.jmedchem.0c00418","article-title":"Nanobodies Targeting Prostate-Specific Membrane Antigen for the Imaging and Therapy of Prostate Cancer","volume":"63","author":"Rosenfeld","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/leu.2013.292","article-title":"Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies","volume":"28","author":"Lemaire","year":"2014","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00259-010-1700-1","article-title":"Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET","volume":"38","author":"Vosjan","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jconrel.2011.12.007","article-title":"Nanobody-coupled microbubbles as novel molecular tracer","volume":"158","author":"Hernot","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Kong, D.H., Kim, Y.K., Kim, M.R., Jang, J.H., and Lee, S. (2018). Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19041057"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Fan, X., Wang, L., Guo, Y., Tu, Z., Li, L., Tong, H., Xu, Y., Li, R., and Fang, K. (2015). Ultrasonic Nanobubbles Carrying Anti-PSMA Nanobody: Construction and Application in Prostate Cancer-Targeted Imaging. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0127419"},{"key":"ref_36","first-page":"535","article-title":"Hypoxia-targeting fluorescent nanobodies for optical molecular imaging of pre-invasive breast cancer","volume":"18","author":"Adams","year":"2015","journal-title":"Mol. Imaging Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1002\/ijc.28601","article-title":"Intraoperative fluorescence delineation of head and neck cancer with a fluorescent anti-epidermal growth factor receptor nanobody","volume":"134","author":"Verbeek","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2310\/7290.2011.00025","article-title":"Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody","volume":"11","author":"Oliveira","year":"2012","journal-title":"Mol. Imaging"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2967\/jnumed.118.224170","article-title":"Early Phase I Study of a 99mTc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT\/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer","volume":"60","author":"Xing","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1470-2045(15)00223-5","article-title":"Global cancer surgery: Delivering safe, affordable, and timely cancer surgery","volume":"16","author":"Sullivan","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Deken, M.M., Bos, D.L., Tummers, W.S.F.J., March, T.L., van de Velde, C.J.H., Rijpkema, M., and Vahrmeijer, A.L. (2019). Multimodal image-guided surgery of HER2-positive breast cancer using [111In]In-DTPA-trastuzumab-IRDye800CW in an orthotopic breast tumor model. EJNMMI Res., 9.","DOI":"10.1186\/s13550-019-0564-z"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1007\/s00259-013-2471-2","article-title":"Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery","volume":"40","author":"Kijanka","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"193","DOI":"10.7150\/ijms.3635","article-title":"Cancer and Radiation Therapy: Current Advances and Future Directions","volume":"9","author":"Baskar","year":"2012","journal-title":"Int. J. Med. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2018.01253","article-title":"Natural Product Interventions for Chemotherapy and Radiotherapy-Induced Side Effects","volume":"9","author":"Zhang","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.apradiso.2010.05.004","article-title":"Toxicity of trastuzumab labeled 177Lu on MCF7 and SKBr3 cell lines","volume":"68","author":"Rasaneh","year":"2010","journal-title":"Appl. Radiat. Isot."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1158\/1535-7163.MCT-17-0554","article-title":"Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma","volume":"16","author":"Krasniqi","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1200\/JCO.2005.18.622","article-title":"Phase II Trial of Carcinoembryonic Antigen Radioimmunotherapy with 131I-Labetuzumab after Salvage Resection of Colorectal Metastases in the Liver: Five-Year Safety and Efficacy Results","volume":"23","author":"Liersch","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.2005.03.4082","article-title":"Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results","volume":"24","author":"Reardon","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1021\/acs.molpharmaceut.0c00580","article-title":"Therapeutic Efficacy of 213Bi-labeled sdAbs in a Preclinical Model of Ovarian Cancer","volume":"17","author":"Dekempeneer","year":"2020","journal-title":"Mol. Pharm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"708","DOI":"10.7150\/thno.8156","article-title":"Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody","volume":"4","author":"Vincke","year":"2014","journal-title":"Theranostics"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/cmmi.408","article-title":"Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice","volume":"6","author":"Gainkam","year":"2011","journal-title":"Contrast Media Mol. Imaging"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Li","year":"2008","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.nbt.2012.09.002","article-title":"Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth","volume":"30","author":"Behdani","year":"2013","journal-title":"N. Biotechnol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-11-0487","article-title":"Antibody fusion proteins: Anti-CD22 recombinant immunotoxin moxetumomab pasudotox","volume":"17","author":"Kreitman","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1200\/JCO.2011.38.1756","article-title":"Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia","volume":"30","author":"Kreitman","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"38568","DOI":"10.18632\/oncotarget.16930","article-title":"Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro","volume":"8","author":"Deng","year":"2017","journal-title":"Oncotarget"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3892\/or.2020.7878","article-title":"Novel EGFR-bispecific recombinant immunotoxin based on cucurmosin shows potent anti-tumor efficiency in vitro","volume":"45","author":"Zhang","year":"2020","journal-title":"Oncol. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Cao, L., Li, Q., Tong, Z., Xing, Y., Xu, K., Wang, J.Y., Li, W., Zhao, J., Zhao, L., and Hong, Z. (2020). HER2-specific immunotoxins constructed based on single-domain antibodies and the improved toxin PE24X7. Int. J. Pharm., 574.","DOI":"10.1016\/j.ijpharm.2019.118939"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jconrel.2010.03.020","article-title":"Downregulation of EGFR by a novel multivalent nanobody-liposome platform","volume":"145","author":"Oliveira","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jconrel.2011.12.027","article-title":"Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment","volume":"159","author":"Oliveira","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jconrel.2011.01.015","article-title":"Nanobody-shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting","volume":"151","author":"Talelli","year":"2011","journal-title":"J. Control. Release"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.biomaterials.2012.09.064","article-title":"Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy","volume":"34","author":"Talelli","year":"2013","journal-title":"Biomaterials"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.biomaterials.2013.10.001","article-title":"Targeting hepatocyte growth factor receptor (Met.) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles","volume":"35","author":"Heukers","year":"2014","journal-title":"Biomaterials"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jconrel.2012.11.007","article-title":"Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells","volume":"165","author":"Altintas","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_66","first-page":"134","article-title":"Principles of cancer treatment by chemotherapy","volume":"36","author":"Dickens","year":"2018","journal-title":"Surgery"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1039\/C8DT00838H","article-title":"The side effects of platinum-based chemotherapy drugs: A review for chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1021\/acs.biomac.9b00947","article-title":"HER2-Specific Reduction-Sensitive Immunopolymersomes with High Loading of Epirubicin for Targeted Treatment of Ovarian Tumor","volume":"20","author":"Ding","year":"2019","journal-title":"Biomacromolecules"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/cbic.201800685","article-title":"Selective Delivery of Doxorubicin to EGFR+ Cancer Cells by Cetuximab-DNA Conjugates","volume":"20","author":"Liu","year":"2019","journal-title":"Chembiochem"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00005-017-0491-5","article-title":"Immunotherapy as an Option for Cancer Treatment","volume":"66","author":"Rusch","year":"2018","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12105","article-title":"Cancer immunoediting: Antigens, mechanisms, and implications to cancer immunotherapy","volume":"1284","author":"Vesely","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: Integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immunosurveillance and immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrc1815","article-title":"Vaccines for tumour prevention","volume":"6","author":"Lollini","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1021\/acs.molpharmaceut.8b00584","article-title":"Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells","volume":"15","author":"An","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Vacchelli, E., Aranda, F., Bloy, N., Buqu\u00e9, A., Cremer, I., Eggermont, A., Fridman, W.H., Fucikova, J., Galon, J., and Spisek, R. (2016). Trial Watch-Immunostimulation with cytokines in cancer therapy. Oncoimmunology, 5.","DOI":"10.1080\/2162402X.2016.1214790"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1158\/0008-5472.CAN-08-0215","article-title":"An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments","volume":"68","author":"Nam","year":"2008","journal-title":"Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/protein\/gzw043","article-title":"Isolation of TGF-\u03b2-neutralizing single-domain antibodies of predetermined epitope specificity using next-generation DNA sequencing","volume":"29","author":"Henry","year":"2016","journal-title":"Protein. Eng. Des. Sel."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"29562","DOI":"10.1074\/jbc.M113.498436","article-title":"Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo","volume":"288","author":"Maussang","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(09)60251-8","article-title":"Monoclonal antibodies for cancer immunotherapy","volume":"373","author":"Weiner","year":"2009","journal-title":"Lancet"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.ejca.2015.08.012","article-title":"Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab","volume":"51","author":"Eroglu","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/1078-0432.CCR-19-1635","article-title":"Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy","volume":"26","author":"Sharma","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_86","first-page":"511","article-title":"Screening and antitumor effect of an anti-CTLA-4 nanobody","volume":"39","author":"Wan","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1166\/jbn.2019.2859","article-title":"A Nanobody Against Cytotoxic T-Lymphocyte Associated Antigen-4 Increases the Anti-Tumor Effects of Specific CD8 + T Cells","volume":"15","author":"Tang","year":"2019","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","article-title":"Role of the PD-1 Pathway in the Immune Response","volume":"12","author":"Riella","year":"2012","journal-title":"Am. J. Transplant."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, in Patients with Refractory Metastatic Urothelial Carcinoma: Results from a Multicenter, Phase Ib Study","volume":"35","author":"Apolo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus Chemotherapy for Squamous Non\u2013Small-Cell Lung Cancer","volume":"379","author":"Luft","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bbrc.2019.08.160","article-title":"Blocking the PD-1-PD-L1 axis by a novel PD-1 specific nanobody expressed in yeast as a potential therapeutic for immunotherapy","volume":"519","author":"Xian","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/10826068.2019.1692217","article-title":"Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)\/PD-1 ligand 1 (PD-1\/PD-L1)","volume":"50","author":"Wen","year":"2020","journal-title":"Prep. Biochem. Biotechnol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10529-020-02823-2","article-title":"Hua, Z. Nanobody against PDL1","volume":"42","author":"Li","year":"2020","journal-title":"Biotechnol. Lett."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Zhang, F., Wei, H., Wang, X., Bai, Y., Wang, P., Wu, J., Jiang, X., Wang, Y., Cai, H., and Xu, T. (2017). Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discov., 3.","DOI":"10.1038\/celldisc.2017.4"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"176","DOI":"10.18632\/genesandcancer.180","article-title":"The promising immune checkpoint LAG-3: From tumor microenvironment to cancer immunotherapy","volume":"9","author":"Long","year":"2018","journal-title":"Genes Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Lecocq, Q., Zeven, K., De Vlaeminck, Y., Martens, S., Massa, S., Goyvaerts, C., Raes, G., Keyaerts, M., Breckpot, K., and Devoogdt, N. (2019). Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use. Biomolecules, 9.","DOI":"10.3390\/biom9100548"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.4049\/jimmunol.172.9.5450","article-title":"Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo","volume":"172","author":"Workman","year":"2004","journal-title":"J. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1172\/JCI31184","article-title":"LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems","volume":"117","author":"Grosso","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1080\/19420862.2019.1629239","article-title":"Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy","volume":"11","author":"Yu","year":"2019","journal-title":"MAbs"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.2147\/OTT.S170385","article-title":"TIM-3, a promising target for cancer immunotherapy","volume":"11","author":"He","year":"2018","journal-title":"Onco. Targets Ther."},{"key":"ref_106","first-page":"1201","article-title":"Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3)","volume":"19","author":"Homayouni","year":"2016","journal-title":"Iran J. Basic Med. Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/ni.2376","article-title":"Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00345-015-1656-7","article-title":"Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma","volume":"34","author":"Cai","year":"2016","journal-title":"World J. Urol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"782","DOI":"10.4049\/jimmunol.1302663","article-title":"T cell Ig and mucin domain-containing protein 3 is recruited to the immune synapse, disrupts stable synapse formation, and associates with receptor phosphatases","volume":"192","author":"Clayton","year":"2014","journal-title":"J. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Zhang, D., Jiang, F., Zaynagetdinov, R., Huang, H., Sood, V.D., Wang, H., Zhao, X., Jenkins, M.H., Ji, Q., and Wang, Y. (2020). Identification and characterization of M6903, an antagonistic anti-TIM-3 monoclonal antibody. Oncoimmunology, 9.","DOI":"10.1080\/2162402X.2020.1744921"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"Guillerey","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s00262-018-2246-5","article-title":"TIGIT: A novel immunotherapy target moving from bench to bedside","volume":"67","author":"Solomon","year":"2018","journal-title":"Cancer Immunol. Immunother"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Callahan, M.K., Postow, M.A., and Wolchok, J.D. (2014). CTLA-4 and PD-1 pathway blockade: Combinations in the clinic. Front. Oncol., 4.","DOI":"10.3389\/fonc.2014.00385"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus Ipilimumab in Advanced Melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"27062","DOI":"10.18632\/oncotarget.16003","article-title":"Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma","volume":"8","author":"Bjoern","year":"2017","journal-title":"Oncotarget"},{"key":"ref_117","first-page":"39","article-title":"Upregulation of Immune Checkpoint Molecules, PD-1 and LAG-3, on CD4+ and CD8+ T Cells after Gastric Cancer Surgery","volume":"58","author":"Takaya","year":"2015","journal-title":"Yonago Acta Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jtho.2017.01.019","article-title":"LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1\/PD-L1 and Tumor-Infiltrating Lymphocytes","volume":"12","author":"He","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"81341","DOI":"10.18632\/oncotarget.13228","article-title":"Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors","volume":"7","author":"Mishra","year":"2016","journal-title":"Oncotarget"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Zuazo, M., Arasanz, H., Fern\u00e1ndez-Hinojal, G., Garc\u00eda-Granda, M.J., Gato, M., Bocanegra, A., Mart\u00ednez, M., Hern\u00e1ndez, B., Teijeira, L., and Morilla, I. (2019). Functional systemic CD4 immunity is required for clinical responses to PD-L1\/PD-1 blockade therapy. EMBO Mol. Med., 11.","DOI":"10.15252\/emmm.201910293"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00595-016-1305-9","article-title":"An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer","volume":"46","author":"Takano","year":"2016","journal-title":"Surg. Today"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/CJI.0000000000000122","article-title":"Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic\/Tumor Vaccines","volume":"39","author":"Liu","year":"2016","journal-title":"J. Immunother."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Koyama, S., Akbay, E.A., Li, Y.Y., Herter-Sprie, G.S., Buczkowski, K.A., Richards, W.G., Gandhi, L., Redig, A.J., Rodig, S.J., and Asahina, H. (2016). Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat. Commun., 7.","DOI":"10.1038\/ncomms10501"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1053\/j.gastro.2017.06.017","article-title":"Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas","volume":"153","author":"Zhou","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1172\/JCI80445","article-title":"TIGIT and PD-1 impair tumor antigen\u2013specific CD8+ T cells in melanoma patients","volume":"125","author":"Chauvin","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.bbrc.2020.07.072","article-title":"A novel bispecific nanobody with PD-L1\/TIGIT dual immune checkpoint blockade","volume":"531","author":"Ma","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"16642","DOI":"10.1073\/pnas.1202832109","article-title":"Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects","volume":"109","author":"Agarwal","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00262-006-0180-4","article-title":"Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR nanobodies","volume":"56","author":"Roovers","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1517\/13543784.2011.600687","article-title":"Development of c-MET pathway inhibitors","volume":"20","author":"Liu","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/neuonc\/noq198","article-title":"A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma","volume":"13","author":"Wen","year":"2011","journal-title":"Neuro-Oncology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1158\/1535-7163.MCT-10-0481","article-title":"TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation","volume":"9","author":"Okamoto","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.4161\/19420862.2014.975099","article-title":"Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction","volume":"6","author":"Huet","year":"2014","journal-title":"MAbs"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/18\/9778\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:00:10Z","timestamp":1760166010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/18\/9778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,10]]},"references-count":133,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["ijms22189778"],"URL":"https:\/\/doi.org\/10.3390\/ijms22189778","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,10]]}}}